Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

0436140 - MBÚ 2015 RIV eng P - Patentový dokument
Šebo, Peter - Leclerc, C. - Osičková, Adriana - Fayolle, C. - Mašín, Jiří - Krůšek, Jan - Osička, Radim - Basler, Marek
Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell.
2014. Vlastník: Institut Pasteur - Mikrobiologický ústav AV ČR, v. v. i. - Fyziologický ústav AV ČR,v. v. i. Datum udělení patentu: 25.06.2014. Číslo patentu: EP2233569
Grant CEP: GA ČR GA310/08/0447; GA MŠMT 2B06161
Institucionální podpora: RVO:61388971 ; RVO:67985823
Klíčová slova: Bordetella pertusis * adenylate cyclase protein
Kód oboru RIV: EE - Mikrobiologie, virologie
http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2233569B1&KC=B1&FT=D&ND=4&date=20140625&DB=worldwide.espacenet.com&locale=en_EP

The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.
Trvalý link: http://hdl.handle.net/11104/0240048